α7 Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment

Neuropharmacology

Volumn 56, Issue 6-7, 2009, Pages 1001-1009

  Thomsen, Morten S ^a,b   Christensen, Ditte Z ^c   Hansen, Henrik H ^a   Redrobe, John P ^a   Mikkelsen, Jens D ^a,d  

^a NEUROSEARCH A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d Mental Health Services CPH   (Denmark)

Author keywords

7 Nicotinic acetylcholine receptor; Arc; Attention; Parvalbumin; Prefrontal cortex; Working memory

Indexed keywords

1,4 DIAZABICYCLO[3.2.2]NONANE 4 CARBOXYLIC ACID 4 BROMOPHENYL ESTER; ACTIVITY REGULATED CYTOSKELETON ASSOCIATED PROTEIN; BUNGAROTOXIN RECEPTOR; CLOZAPINE; HALOPERIDOL; MESSENGER RNA; METHYLLYCACONITINE; PARVALBUMIN; PHENCYCLIDINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG ANTAGONISM; DRUG DOSE COMPARISON; IN SITU HYBRIDIZATION; MALE; MOUSE; NEUROMODULATION; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA; WORKING MEMORY;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; COGNITION DISORDERS; CYTOSKELETAL PROTEINS; DRUG PARTIAL AGONISM; GENE EXPRESSION; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; NICOTINIC AGONISTS; PARVALBUMINS; PHENCYCLIDINE; PREFRONTAL CORTEX; RECEPTORS, GABA-A; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NICOTINIC; RNA, MESSENGER; SYNAPTOPHYSIN;

EID: 67349085106     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.02.003     Document Type: Article

References (62)

1. Alkondon M., Pereira E.F., Eisenberg H.M., and Albuquerque E.X. Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J. Neurosci. 20 (2000) 66-75
2. Arias H.R., Bhumireddy P., and Bouzat C. Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors. Int. J. Biochem. Cell Biol. 38 (2006) 1254-1276
3. Behrens M.M., Ali S.S., Dao D.N., Lucero J., Shekhtman G., Quick K.L., and Dugan L.L. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 318 (2007) 1645-1647
4. Benes F.M., and Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25 (2001) 1-27
5. Bitner R.S., Bunnelle W.H., Anderson D.J., Briggs C.A., Buccafusco J., Curzon P., Decker M.W., Frost J.M., Gronlien J.H., Gubbins E., Li J., Malysz J., Markosyan S., Marsh K., Meyer M.D., Nikkel A.L., Radek R.J., Robb H.M., Timmermann D., Sullivan J.P., and Gopalakrishnan M. Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J. Neurosci. 27 (2007) 10578-10587
6. Boess F.G., De Vry J., Erb C., Flessner T., Hendrix M., Luithle J., Methfessel C., Riedl B., Schnizler K., van der Staay F.J., van Kampen M., Wiese W.B., and Koenig G. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. J. Pharmacol. Exp. Ther. 321 (2007) 716-725
7. Breese C.R., Lee M.J., Adams C.E., Sullivan B., Logel J., Gillen K.M., Marks M.J., Collins A.C., and Leonard S. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23 (2000) 351-364
8. Cochran S.M., Fujimura M., Morris B.J., and Pratt J.A. Acute and delayed effects of phencyclidine upon mRNA levels of markers of glutamatergic and GABAergic neurotransmitter function in the rat brain. Synapse 46 (2002) 206-214
9. Cochran S.M., Kennedy M., McKerchar C.E., Steward L.J., Pratt J.A., and Morris B.J. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28 (2003) 265-275
10. Coyle J.T. The GABA-glutamate connection in schizophrenia: which is the proximate cause?. Biochem. Pharmacol. 68 (2004) 1507-1514
11. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol. 26 (2006) 365-384
12. Dalley J.W., Cardinal R.N., and Robbins T.W. Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci. Biobehav. Rev. 28 (2004) 771-784
13. Faw B. Pre-frontal executive committee for perception, working memory, attention, long-term memory, motor control, and thinking: a tutorial review. Conscious Cogn. 12 (2003) 83-139
14. Franklin K.B.J., and Paxinos G. The Mouse Brain in Stereotaxic Coordinates (2007), Academic Press
15. Freedman R., Olincy A., Buchanan R.W., Harris J.G., Gold J.M., Johnson L., Allensworth D., Guzman-Bonilla A., Clement B., Ball M.P., Kutnick J., Pender V., Martin L.F., Stevens K.E., Wagner B.D., Zerbe G.O., Soti F., and Kem W.R. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry 165 (2008) 1040-1047
16. Gao X.M., Hashimoto T., and Tamminga C.A. Phencyclidine (PCP) and dizocilpine (MK801) exert time-dependent effects on the expression of immediate early genes in rat brain. Synapse 29 (1998) 14-28
17. Gao X.M., Shirakawa O., Du F., and Tamminga C.A. Delayed regional metabolic actions of phencyclidine. Eur. J. Pharmacol. 241 (1993) 7-15
18. Glantz L.A., and Lewis D.A. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch. Gen. Psychiatry 54 (1997) 660-669
19. Glantz L.A., and Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry 57 (2000) 65-73
20. 2+ dynamics. J. Physiol. 551 (2003) 67-78
21. Gotoh L., Kawanami N., Nakahara T., Hondo H., Motomura K., Ohta E., Kanchiku I., Kuroki T., Hirano M., and Uchimura H. Effects of the adenosine A(1) receptor agonist N(6)-cyclopentyladenosine on phencyclidine-induced behavior and expression of the immediate-early genes in the discrete brain regions of rats. Brain Res. Mol. Brain Res. 100 (2002) 1-12
22. Green M.F., Kern R.S., and Heaton R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res. 72 (2004) 41-51
23. Grunze H.C., Rainnie D.G., Hasselmo M.E., Barkai E., Hearn E.F., McCarley R.W., and Greene R.W. NMDA-dependent modulation of CA1 local circuit inhibition. J. Neurosci. 16 (1996) 2034-2043
24. Guan Z.Z., Zhang X., Blennow K., and Nordberg A. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. NeuroReport 10 (1999) 1779-1782
25. Guzowski J.F., McNaughton B.L., Barnes C.A., and Worley P.F. Environment-specific expression of the immediate-early gene Arc in hippocampal neuronal ensembles. Nat. Neurosci. 2 (1999) 1120-1124
26. Hajszan T., Leranth C., and Roth R.H. Subchronic phencyclidine treatment decreases the number of dendritic spine synapses in the rat prefrontal cortex. Biol. Psychiatry 60 (2006) 639-644
27. Hashimoto K., Ishima T., Fujita Y., Matsuo M., Kobashi T., Takahagi M., Tsukada H., and Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. Biol. Psychiatry 63 (2008) 92-97
28. Hughes R.N. The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci. Biobehav. Rev. 28 (2004) 497-505
29. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
30. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
31. Keefe R.S., Silva S.G., Perkins D.O., and Lieberman J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. 25 (1999) 201-222
32. Kinney J.W., Davis C.N., Tabarean I., Conti B., Bartfai T., and Behrens M.M. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J. Neurosci. 26 (2006) 1604-1615
33. Krenz I., Kalkan D., Wevers A., de Vos R.A., Steur E.N., Lindstrom J., Pilz K., Nowacki S., Schutz U., Moser N., Witter B., and Schroder H. Parvalbumin-containing interneurons of the human cerebral cortex express nicotinic acetylcholine receptor proteins. J. Chem. Neuroanat. 21 (2001) 239-246
34. Kristensen S.E., Thomsen M.S., Hansen H.H., Timmermann D.B., Hay-Schmidt A., and Mikkelsen J.D. The alpha7 nicotinic receptor agonist SSR180711 increases activity regulated cytoskeleton protein (Arc) gene expression in the prefrontal cortex of the rat. Neurosci. Lett. 418 (2007) 154-158
35. Lalonde R. The neurobiological basis of spontaneous alternation. Neurosci. Biobehav. Rev. 26 (2002) 91-104
36. Larsen M.H., Hay-Schmidt A., Ronn L.C., and Mikkelsen J.D. Temporal expression of brain-derived neurotrophic factor (BDNF) mRNA in the rat hippocampus after treatment with selective and mixed monoaminergic antidepressants. Eur. J. Pharmacol. 578 (2008) 114-122
37. Larsen M.H., Olesen M., Woldbye D.P., Hay-Schmidt A., Hansen H.H., Ronn L.C., and Mikkelsen J.D. Regulation of activity-regulated cytoskeleton protein (Arc) mRNA after acute and chronic electroconvulsive stimulation in the rat. Brain Res. 1064 (2005) 161-165
38. Leonard S., Gault J., Hopkins J., Logel J., Vianzon R., Short M., Drebing C., Berger R., Venn D., Sirota P., Zerbe G., Olincy A., Ross R.G., Adler L.E., and Freedman R. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch. Gen. Psychiatry 59 (2002) 1085-1096
39. Levin E.D., McClernon F.J., and Rezvani A.H. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl.) 184 (2006) 523-539
40. Lewis D.A., and Gonzalez-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 33 (2008) 141-165
41. Lewis D.A., Hashimoto T., and Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6 (2005) 312-324
42. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., and Grace A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 31 (2008) 234-242
43. Liu X.B., and Jones E.G. Localization of alpha type II calcium calmodulin-dependent protein kinase at glutamatergic but not gamma-aminobutyric acid (GABAergic) synapses in thalamus and cerebral cortex. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 7332-7336
44. Martin L.F., Kem W.R., and Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl.) 174 (2004) 54-64
45. Marutle A., Zhang X., Court J., Piggott M., Johnson M., Perry R., Perry E., and Nordberg A. Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J. Chem. Neuroanat. 22 (2001) 115-126
46. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 40 (2003) 881-884
47. Morrow B.A., Elsworth J.D., and Roth R.H. Repeated phencyclidine in monkeys results in loss of parvalbumin-containing axo-axonic projections in the prefrontal cortex. Psychopharmacology (Berl.) 192 (2007) 283-290
48. Moser N., Mechawar N., Jones I., Gochberg-Sarver A., Orr-Urtreger A., Plomann M., Salas R., Molles B., Marubio L., Roth U., Maskos U., Winzer-Serhan U., Bourgeois J.P., Le Sourd A.M., De Biasi M., Schroder H., Lindstrom J., Maelicke A., Changeux J.P., and Wevers A. Evaluating the suitability of nicotinic acetylcholine receptor antibodies for standard immunodetection procedures. J. Neurochem. 102 (2007) 479-492
49. Mouri A., Noda Y., Enomoto T., and Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem. Int. 51 (2007) 173-184
50. Olincy A., Harris J.G., Johnson L.L., Pender V., Kongs S., Allensworth D., Ellis J., Zerbe G.O., Leonard S., Stevens K.E., Stevens J.O., Martin L., Adler L.E., Soti F., Kem W.R., and Freedman R. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry 63 (2006) 630-638
51. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52 (1995) 998-1007
52. Olney J.W., Labruyere J., and Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244 (1989) 1360-1362
53. Pei Q., Zetterström T.S., Sprakes M., Tordera R., and Sharp T. Antidepressant drug treatment induces Arc gene expression in the rat brain. Neuroscience 121 (2003) 975-982
54. Pichat P., Bergis O.E., Terranova J.P., Urani A., Duarte C., Santucci V., Gueudet C., Voltz C., Steinberg R., Stemmelin J., Oury-Donat F., Avenet P., Griebel G., and Scatton B. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32 (2007) 17-34
55. Redrobe J.P., Nielsen E.O., Christensen J.K., Peters D., Timmermann D.B., and Olsen G.M. Alpha7 nicotinic acetylcholine receptor activation ameliorates scopolamine-induced behavioural changes in a modified continuous Y-maze task in mice. Eur. J. Pharmacol. 602 (2009) 58-65
56. Rodefer J.S., Murphy E.R., and Baxter M.G. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur. J. Neurosci. 21 (2005) 1070-1076
57. Song C., Murray T.A., Kimura R., Wakui M., Ellsworth K., Javedan S.P., Marxer-Miller S., Lukas R.J., and Wu J. Role of alpha7-nicotinic acetylcholine receptors in tetanic stimulation-induced gamma oscillations in rat hippocampal slices. Neuropharmacology 48 (2005) 869-880
58. Thomsen M.S., Mikkelsen J.D., Timmermann D.B., Peters D., Hay-Schmidt A., Martens H., and Hansen H.H. The selective alpha7 nicotinic acetylcholine receptor agonist A-582941 activates immediate early genes in limbic regions of the forebrain: differential effects in the juvenile and adult rat. Neuroscience 154 (2008) 741-753
59. Tzingounis A.V., and Nicoll R.A. Arc/Arg3.1: linking gene expression to synaptic plasticity and memory. Neuron 52 (2006) 403-407
60. Vazdarjanova A., Ramirez-Amaya V., Insel N., Plummer T.K., Rosi S., Chowdhury S., Mikhael D., Worley P.F., Guzowski J.F., and Barnes C.A. Spatial exploration induces ARC, a plasticity-related immediate-early gene, only in calcium/calmodulin-dependent protein kinase II-positive principal excitatory and inhibitory neurons of the rat forebrain. J. Comp. Neurol. 498 (2006) 317-329
61. Wang C., McInnis J., Ross-Sanchez M., Shinnick-Gallagher P., Wiley J.L., and Johnson K.M. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107 (2001) 535-550
62. Woodward N.D., Purdon S.E., Meltzer H.Y., and Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 8 (2005) 457-472